Carcinoid tumors are slow-growing neuroendocrine tumors that arise from hormone-producing cells scattered throughout the body, most commonly in the gastrointestinal tract and lungs. Despite their relatively quiet behavior compared to many other cancers, they can produce a dramatic set of symptoms when they release excess hormones into the bloodstream. The term “carcinoid” itself hints at this duality, and the science behind these tumors turns out to be more layered than most people expect.
Where Carcinoid Tumors Come From
Carcinoid tumors originate from enterochromaffin cells, a type of specialized cell embedded in the lining of organs that produces hormones and other signaling molecules.1The Oncologist. Metastatic Carcinoid Tumors: A Clinical Review These cells are found in many places, which is why carcinoid tumors can show up almost anywhere. The name itself dates to 1907, when the German pathologist Siegfried Oberndorfer coined the term “karzinoide,” meaning “carcinoma-like,” to describe small intestinal tumors that looked like cancer under the microscope but behaved far more gently. He later revised that assessment in 1929, acknowledging that these tumors could in fact become malignant and spread.2PubMed. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors
That tension between “benign-looking” and “potentially dangerous” still defines how doctors think about carcinoid tumors today. Many grow so slowly that a person can carry one for years without knowing it. Others metastasize to the liver and other organs, triggering the hormonal storm known as carcinoid syndrome.
Where in the Body They Appear
Roughly 55% of carcinoid tumors are found in the gastrointestinal tract and about 30% in the lungs and airways.3PubMed Central. Carcinoid Tumors Within the GI tract, the small intestine is by far the most common site, accounting for around 45% of GI carcinoids, followed by the rectum at 20%, the appendix at 17%, the colon at 11%, and the stomach at 7%.4PubMed Central. Carcinoid Tumors Rarer locations include the thymus, ovaries, and kidneys, though these are uncommon enough that they often surprise even the surgeons who find them.
The site of origin matters beyond anatomy. Gastrointestinal and lung carcinoids differ at the molecular level. Studies comparing chromosomal changes in the two groups have found strikingly different patterns of DNA loss: GI tumors frequently lose material on chromosome 18, while bronchial tumors tend to lose material on chromosome 11q instead, suggesting the two develop through distinct molecular pathways.5PubMed Central. Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis This is one reason why a carcinoid in the lung and a carcinoid in the ileum are not simply the same disease in a different zip code.
Carcinoid Syndrome and How It Develops
The most feared complication of carcinoid tumors is carcinoid syndrome, a cluster of symptoms caused by hormones the tumor secretes into the bloodstream. The hallmark features include episodes of skin flushing, persistent diarrhea, wheezing, and sometimes an unusual purplish discoloration of the skin.6PubMed Central. Factors responsible for the carcinoid spectrum. A review Serotonin is the best-established culprit behind the diarrhea and the tissue fibrosis that can develop over time, though tachykinins and catecholamines also appear to play a role.7Endocrine Reviews. What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators Other substances once thought to be major players, including histamine, bradykinin, and prostaglandins, have weaker evidence behind them than many textbooks suggest.8Endocrine Reviews. What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators
Here is the important part most people miss: a carcinoid tumor in the gut does not usually cause carcinoid syndrome until it has spread to the liver. The reason is that the liver normally filters serotonin and other active substances out of portal blood before they reach the rest of the body. Once tumor deposits are living inside the liver itself, their secretions bypass that filter and flood the systemic circulation. Only about 10% of patients with GI carcinoid tumors that have metastasized to the liver develop the full syndrome.9PubMed Central. Flushing: A Diagnostic Dilemma Lung and stomach carcinoids, by contrast, can occasionally trigger symptoms even without liver metastases because their hormonal output drains directly into the systemic bloodstream.10PubMed Central. Flushing: A Diagnostic Dilemma
Carcinoid Heart Disease
One of the more insidious consequences of long-standing carcinoid syndrome is damage to the heart. Serotonin and related substances promote the deposit of fibrous tissue on the inner surface of heart valves, particularly on the right side. The characteristic finding is thickening and stiffening of the tricuspid and pulmonary valves, which can lead to right-sided heart failure over time.11PubMed Central. Valvular Disorders in Carcinoid Heart Disease The left side of the heart is usually spared because the lungs metabolize serotonin before blood reaches the left atrium. Carcinoid heart disease is one of the main reasons aggressive management of the hormone-secreting tumor matters even when the tumor itself is growing slowly: the cardiac damage, once established, is difficult to reverse and may ultimately require valve-replacement surgery.
How Carcinoid Tumors Are Found and Graded
Many carcinoid tumors are discovered incidentally during surgery or imaging for an unrelated problem, particularly appendiceal carcinoids found during appendectomies. When doctors do go looking for them, a combination of blood and urine tests (measuring markers such as chromogranin A and urinary 5-HIAA, a serotonin breakdown product) and advanced imaging is used. The workhorse imaging tool has become gallium-68 DOTATATE PET/CT, a scan that lights up tumors rich in somatostatin receptors. It has become the preferred method for initial diagnosis, for finding unknown primary tumors, and for deciding whether a patient is a candidate for targeted radionuclide therapy.12PubMed. Neuroendocrine Tumor Diagnosis and Management: (68)Ga-DOTATATE PET/CT
The scan works especially well for well-differentiated, slower-growing tumors. In studies of pulmonary carcinoids, typical carcinoids showed dramatically higher tracer uptake than higher-grade tumors.13Journal of Nuclear Medicine. A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors More aggressive tumors, which lose their somatostatin receptors, tend to light up instead on standard FDG-PET scans, the same type of scan used for most other cancers. This flip-flop is a useful clinical clue: a carcinoid that shows up brightly on FDG-PET but barely on DOTATATE is behaving more aggressively.
Grading relies on how fast the tumor cells are dividing. The Ki-67 proliferation index, which measures the percentage of cells actively replicating, is essential for distinguishing low-grade tumors from intermediate and high-grade ones and guides both prognosis and treatment decisions.14PubMed. Optimal Approaches to Grading Enteropancreatic Neuroendocrine Tumors Using Ki-67 Proliferation Index: Hotspot and Whole-Slide Digital Quantitative Analysis Studies have found Ki-67 more reliable than counting mitotic figures under the microscope for classifying these tumors.15PubMed Central. Ki-67 is a powerful tool for grading neuroendocrine tumors among Egyptian patients: a 10-year experience That said, grading is not destiny. At least one study found no statistically significant correlation between the Ki-67 value itself and the presence of metastases in gastroenteropancreatic tumors, a reminder that biology does not always follow the numbers neatly.16PubMed Central. Comparison of Mitotic Count and Ki-67 Index in Grading Gastroenteropancreatic Neuroendocrine Tumors and Their Association with Metastases
Typical Versus Atypical Carcinoids
In the lungs especially, carcinoid tumors are divided into two categories that behave quite differently. Typical carcinoids are well-differentiated, have low proliferation rates, and carry good survival rates. Atypical carcinoids are more aggressive, more likely to involve lymph nodes, and have considerably worse outcomes.17CHEST. Pulmonary Carcinoid Tumors Involving Regional Thoracic Lymph Nodes The distinction is made under the microscope by counting mitotic figures and looking for areas of necrosis, but Ki-67 staining can also help identify the higher-risk patients within the atypical group who might benefit from additional treatment after surgery.18Human Pathology. Typical and atypical bronchopulmonary carcinoid tumors: A clinicopathologic and Kl-67-labeling study
The practical significance here is that “carcinoid” is not a single prognosis. Hearing that you have a typical bronchial carcinoid is a fundamentally different conversation from hearing you have an atypical one with lymph node involvement. Patients understandably latch onto the word “carcinoid” and its reputation for slow growth, but the range of behavior within this family of tumors is wide.
Treatment Options
Surgery remains the first-line treatment whenever the tumor can be fully removed. For localized carcinoids, complete resection is curative in many cases. Even in patients with liver metastases, surgery has a role, because the slow growth rate of many carcinoid tumors means that reducing the tumor burden can relieve symptoms and extend life, sometimes dramatically.19PubMed. Treatment of liver metastases of carcinoid tumors One study using expanded criteria for liver debulking, allowing removal of as little as 70% of visible tumor rather than the traditional 90% threshold, reported a five-year disease-specific survival of 90%.20PubMed. Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients
For tumors that cannot be fully removed or that have spread beyond the reach of surgery, somatostatin analogs such as octreotide and lanreotide have long been the backbone of treatment. These drugs were originally used just to control symptoms like flushing and diarrhea, but evidence now supports a direct antitumor effect as well, slowing growth even in tumors that are not actively producing hormones.21PubMed Central. Antitumor effects of somatostatin analogs in neuroendocrine tumors The landmark PROMID trial showed that long-acting octreotide more than doubled median time to tumor progression compared to placebo in patients with metastatic midgut carcinoids, from 6 months to about 14 months.22PubMed. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group The strongest benefit was seen in patients with low tumor burden in the liver and whose primary tumor had already been removed.
When somatostatin analogs stop working or tumors progress, peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE has become an established option. This treatment delivers targeted radiation directly to tumor cells that express somatostatin receptors, and clinical evidence supports its ability to slow disease progression and improve quality of life.23PubMed Central. A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients Beyond tumor control, PRRT has also been shown to reduce carcinoid syndrome symptoms specifically. In one study, patients with refractory flushing saw reductions of more than 50% in daily flushing episodes in two-thirds of cases, and a meaningful decrease in diarrhea frequency as well.24The Journal of Clinical Endocrinology & Metabolism. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
For patients whose diarrhea remains uncontrolled despite somatostatin analogs, telotristat ethyl offers a different mechanism. It blocks tryptophan hydroxylase, the enzyme that converts tryptophan into a serotonin precursor, reducing serotonin production at its source.25Springer Link / PubMed Central. Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications
Why Some Tumors Stop Responding to Treatment
A frustrating reality in carcinoid management is that somatostatin analogs, despite being the cornerstone of therapy, can lose their effectiveness over time. Resistance develops through several mechanisms, including changes in the somatostatin receptors the drugs bind to, as well as additional genetic and epigenetic alterations within the tumor.26PubMed. Resistance of neuroendocrine tumours to somatostatin analogs This is a complex and still incompletely understood phenomenon. When resistance emerges, clinicians typically escalate to PRRT, targeted therapies like everolimus, or consider cytoreductive surgery and liver-directed therapies such as hepatic artery embolization. The good news is that the treatment landscape has expanded considerably over the past two decades, so running out of options is less common than it used to be.
Rising Incidence
Carcinoid tumors are being diagnosed more frequently than in previous decades, and the reasons are not entirely straightforward. In Germany, for example, the overall incidence of gastroenteropancreatic neuroendocrine tumors rose from roughly 0.3 per 100,000 people per year in 1976 to over 2.2 per 100,000 by 2006.27PubMed Central. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany Similar trends have been documented in other countries. Part of this increase is genuine, but a substantial part reflects better detection: improvements in endoscopy, cross-sectional imaging, and pathologists’ awareness have caught tumors that would have gone unnoticed a generation ago.28PubMed. Multimodality Imaging Findings in Carcinoid Tumors: A Head-to-Toe Spectrum The small intestine remains the most common GI site overall, but rectal carcinoids have shown the fastest relative increase in detection, likely because of widespread screening colonoscopy.
Genetic Connections
Most carcinoid tumors occur sporadically, with no identifiable inherited cause. The exception is multiple endocrine neoplasia type 1 (MEN1), a genetic syndrome caused by mutations in the MEN1 gene. About 10% of individuals with MEN1 develop carcinoid tumors, typically in the thymus, bronchi, or stomach.29Genetics in Medicine. Multiple endocrine neoplasia type 1 (MEN1): Not only inherited endocrine tumors This means that a family history of MEN1, or a personal history of multiple endocrine tumors (parathyroid, pituitary, and pancreatic tumors are the classic triad), should prompt screening for carcinoid tumors as well. For people without a known genetic syndrome, there is no routine screening recommendation, and the tumors are generally found either through symptoms or incidentally.
Living with Carcinoid Syndrome
The daily experience of carcinoid syndrome is often more debilitating than the tumor itself. Unpredictable flushing episodes can be socially isolating, and frequent diarrhea can make it difficult to travel, work, or maintain normal routines. Research has shown that having four or more bowel movements per day is associated with meaningfully lower quality-of-life scores across physical, social, emotional, and functional domains, and each additional symptom compounds the impact further.30PubMed Central. Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome Sustained improvements in bowel frequency, when treatment achieves them, appear to translate into broader gains in overall well-being.31PubMed. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR
The economic burden is considerable as well. Patients with carcinoid syndrome incur higher treatment costs and use more healthcare resources than those with neuroendocrine tumors without the syndrome, largely because symptom management requires ongoing medication, imaging surveillance, and sometimes repeated procedural interventions.32PubMed Central. A review of economic and quality of life research in carcinoid syndrome
Niacin Deficiency and Pellagra
One underrecognized complication of carcinoid tumors deserves a mention because it is easily treatable once suspected. When a tumor diverts large amounts of the amino acid tryptophan into serotonin production, the body’s supply of tryptophan for making niacin (vitamin B3) can become depleted. The result is pellagra, classically described by the “three Ds”: dermatitis, diarrhea, and dementia. Because diarrhea is already a symptom of carcinoid syndrome, the skin changes may be the first clue that something else is going on. Clinicians are now advised to suspect niacin deficiency in any neuroendocrine tumor patient who develops chronic diarrhea combined with new skin changes, and to consider starting nicotinamide supplementation even before lab confirmation, since testing for niacin levels is not always readily available.33PubMed Central. Pellagra From Tryptophan Depletion in Carcinoid Syndrome due to a Pulmonary Atypical Carcinoid Neuroendocrine Tumor A simple vitamin can prevent a serious neurological complication, but only if someone thinks to look for it.